Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a muscle relaxant stop deadly heart rhythms?

NCT ID NCT04134845

Disease control Sponsor: Vanderbilt University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a single dose of dantrolene, a muscle relaxant, could reduce the risk of dangerous heart rhythms in 68 people with structural heart disease who were scheduled for a procedure to treat ventricular tachycardia. Participants received either dantrolene or a placebo, and researchers measured if the drug made it harder to trigger a dangerous heart rhythm. The goal was to see if dantrolene could be a new tool to control heart rhythm problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dantrolene (a muscle relaxant)
What this could lead to
If it works, this could point toward a new way to prevent dangerous heart rhythms in people with heart disease.
What could go wrong
This is a small, early-phase trial with only 68 participants, so results may not apply to everyone. Dantrolene is a muscle relaxant and may cause side effects like muscle weakness or liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

68 people

The number who actually took part.

Started

Aug 2020

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Greater than or equal to 18 years of age * Able to give written informed consent * Referred for catheter-based VT ablation * Structural heart disease (cardiomyopathy or RV/LV scar) * Permanent pacemaker or implantable cardioverter defibrillator Exclusion Criteria: * Mechanical ventricular support (e.g. LVAD, ECMO) * NYHA class IV heart failure * LVEF \< 20% * Morbid obesity (BMI \> 40 kg/m2) * Severe renal insufficiency (GFR\<30 mL/min) * Chronic liver disease (Child Pugh class A-C) * Current use of calcium channel blockers * Neuromuscular disorder (e.g. muscular dystrophy) * Chronic obstructive pulmonary disease or restrictive lung disease requiring oxygen * Therapy or history of intubation * Pregnant or nursing * History of dysphagia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Structural heart disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart disorder ventricular tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ventricular tachycardia

Contacts and locations

Locations

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.